OncoMatch/Clinical Trials/NCT06875310
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Is NCT06875310 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for carcinoma, non-small-cell lung.
Treatment: Adagrasib · Pembrolizumab · Carboplatin · Pemetrexed · Cisplatin — This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any expression (0 to 100%)
Required: KRAS g12c mutation
Prior therapy
Cannot have received: KRAS inhibitor (sotorasib, adagrasib)
Treatment targeting KRAS G12C mutation (eg, sotorasib, adagrasib) in any setting.
Lab requirements
Blood counts
Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities [excluded]
Liver function
Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities [excluded]
Cardiac function
ECG abnormalities [excluded]; ongoing treatment with concomitant medication known to cause prolonged QTc interval and that cannot be switched to alternative treatment prior to study entry [excluded]
Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities. Ongoing treatment with concomitant medication known to cause prolonged QTc interval and that cannot be switched to alternative treatment prior to study entry.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0347 · Birmingham, Alabama
- Local Institution - 0686 · Springdale, Arkansas
- Local Institution - 0581 · Fullerton, California
- Local Institution - 0682 · Loma Linda, California
- Local Institution - 0202 · Long Beach, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06875310 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 any expression is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS g12c mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify